POINT Biopharma Global Inc.

POINT Biopharma Global Inc. (Nasdaq: PNT) is a radiopharmaceutical company that entered public markets through a business combination with GX Acquisition Corp. II, a blank-check vehicle sponsored by GX Capital Management that completed its initial public offering in 2021. The company is focused on developing and commercializing targeted radioligand therapies for oncology, operating within the biotechnology and radiopharmaceutical sector. POINT Biopharma filed an 8-K current report with the U.S. Securities and Exchange Commission on June 5, 2023, under accession number 0001811764-23-000023, disclosing a material corporate event during its post-merger public phase. For complete filing history, sponsor details, and real-time SPAC analytics on PNT, sign up for full data on SpacDesk.